250 related articles for article (PubMed ID: 28330901)
1. Azacitidine Mitigates Graft-versus-Host Disease via Differential Effects on the Proliferation of T Effectors and Natural Regulatory T Cells In Vivo.
Cooper ML; Choi J; Karpova D; Vij K; Ritchey J; Schroeder MA; DiPersio JF
J Immunol; 2017 May; 198(9):3746-3754. PubMed ID: 28330901
[TBL] [Abstract][Full Text] [Related]
2. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia.
Choi J; Ritchey J; Prior JL; Holt M; Shannon WD; Deych E; Piwnica-Worms DR; DiPersio JF
Blood; 2010 Jul; 116(1):129-39. PubMed ID: 20424188
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic expansion of donor-derived, naturally occurring CD4(+)Foxp3(+) regulatory T cells reduces acute graft-versus-host disease lethality without abrogating the graft-versus-leukemia effect in murine models.
Duramad O; Laysang A; Li J; Ishii Y; Namikawa R
Biol Blood Marrow Transplant; 2011 Aug; 17(8):1154-68. PubMed ID: 21145405
[TBL] [Abstract][Full Text] [Related]
4. Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease.
Pillai AB; George TI; Dutt S; Strober S
Blood; 2009 Apr; 113(18):4458-67. PubMed ID: 19221040
[TBL] [Abstract][Full Text] [Related]
5. Induced regulatory T cells promote tolerance when stabilized by rapamycin and IL-2 in vivo.
Zhang P; Tey SK; Koyama M; Kuns RD; Olver SD; Lineburg KE; Lor M; Teal BE; Raffelt NC; Raju J; Leveque L; Markey KA; Varelias A; Clouston AD; Lane SW; MacDonald KP; Hill GR
J Immunol; 2013 Nov; 191(10):5291-303. PubMed ID: 24123683
[TBL] [Abstract][Full Text] [Related]
6. CD4+ invariant natural killer T cells protect from murine GVHD lethality through expansion of donor CD4+CD25+FoxP3+ regulatory T cells.
Schneidawind D; Pierini A; Alvarez M; Pan Y; Baker J; Buechele C; Luong RH; Meyer EH; Negrin RS
Blood; 2014 Nov; 124(22):3320-8. PubMed ID: 25293774
[TBL] [Abstract][Full Text] [Related]
7. Blockade of chronic graft-versus-host disease by alloantigen-induced CD4+CD25+Foxp3+ regulatory T cells in nonlymphopenic hosts.
Giorgini A; Noble A
J Leukoc Biol; 2007 Nov; 82(5):1053-61. PubMed ID: 17684039
[TBL] [Abstract][Full Text] [Related]
8. Donor Requirements for Regulatory T Cell Suppression of Murine Graft-versus-Host Disease.
Pierini A; Colonna L; Alvarez M; Schneidawind D; Nishikii H; Baker J; Pan Y; Florek M; Kim BS; Negrin RS
J Immunol; 2015 Jul; 195(1):347-55. PubMed ID: 25994967
[TBL] [Abstract][Full Text] [Related]
9. HIF-1α inhibitor echinomycin reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect.
Yao Y; Wang L; Zhou J; Zhang X
J Transl Med; 2017 Feb; 15(1):28. PubMed ID: 28183349
[TBL] [Abstract][Full Text] [Related]
10. Efficient and selective prevention of GVHD by antigen-specific induced Tregs via linked-suppression in mice.
Semple K; Yu Y; Wang D; Anasetti C; Yu XZ
Biol Blood Marrow Transplant; 2011 Mar; 17(3):309-18. PubMed ID: 21224010
[TBL] [Abstract][Full Text] [Related]
11. Engineered regulatory T cells prevent graft-versus-host disease while sparing the graft-versus-leukemia effect after bone marrow transplantation.
Cao J; Chen C; Zeng L; Li L; Li Z; Xu K
Leuk Res; 2010 Oct; 34(10):1374-82. PubMed ID: 20018376
[TBL] [Abstract][Full Text] [Related]
12. Amelioration of acute graft-versus-host disease by adoptive transfer of ex vivo expanded human cord blood CD4+CD25+ forkhead box protein 3+ regulatory T cells is associated with the polarization of Treg/Th17 balance in a mouse model.
Yang J; Fan H; Hao J; Ren Y; Chen L; Li G; Xie R; Yang Y; Qian K; Liu M
Transfusion; 2012 Jun; 52(6):1333-47. PubMed ID: 22098312
[TBL] [Abstract][Full Text] [Related]
13. Constitutively active Stat5b in CD4+ T cells inhibits graft-versus-host disease lethality associated with increased regulatory T-cell potency and decreased T effector cell responses.
Vogtenhuber C; Bucher C; Highfill SL; Koch LK; Goren E; Panoskaltsis-Mortari A; Taylor PA; Farrar MA; Blazar BR
Blood; 2010 Jul; 116(3):466-74. PubMed ID: 20442366
[TBL] [Abstract][Full Text] [Related]
14. Recipient type-specific engineered regulatory T cells prevent graft-vs-host disease after allogeneic bone marrow transplantation in mice.
Chen C; Cao J; Zeng L; Li Y; Wang D; Xu K
Transplant Proc; 2011 Jun; 43(5):2041-8. PubMed ID: 21693322
[TBL] [Abstract][Full Text] [Related]
15. Ex vivo expanded human CD4+CD25+Foxp3+ regulatory T cells prevent lethal xenogenic graft versus host disease (GVHD).
Cao T; Soto A; Zhou W; Wang W; Eck S; Walker M; Harriman G; Li L
Cell Immunol; 2009; 258(1):65-71. PubMed ID: 19410243
[TBL] [Abstract][Full Text] [Related]
16. Marked in Vivo Donor Regulatory T Cell Expansion via Interleukin-2 and TL1A-Ig Stimulation Ameliorates Graft-versus-Host Disease but Preserves Graft-versus-Leukemia in Recipients after Hematopoietic Stem Cell Transplantation.
Wolf D; Barreras H; Bader CS; Copsel S; Lightbourn CO; Pfeiffer BJ; Altman NH; Podack ER; Komanduri KV; Levy RB
Biol Blood Marrow Transplant; 2017 May; 23(5):757-766. PubMed ID: 28219835
[TBL] [Abstract][Full Text] [Related]
17. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
Xia G; Truitt RL; Johnson BD
Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
[TBL] [Abstract][Full Text] [Related]
18. Prevention of graft-versus-host diseases by in vivo supCD28mAb-expanded antigen-specific nTreg cells.
Kitazawa Y; Li XK; Liu Z; Kimura H; Isaka Y; Hünig T; Takahara S
Cell Transplant; 2010; 19(6):765-74. PubMed ID: 20573297
[TBL] [Abstract][Full Text] [Related]
19. Oral combined therapy with probiotics and alloantigen induces B cell-dependent long-lasting specific tolerance.
Mercadante AC; Perobelli SM; Alves AP; Gonçalves-Silva T; Mello W; Gomes-Santos AC; Miyoshi A; Azevedo V; Faria AM; Bonomo A
J Immunol; 2014 Feb; 192(4):1928-37. PubMed ID: 24453248
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting.
Sánchez-Abarca LI; Gutierrez-Cosio S; Santamaría C; Caballero-Velazquez T; Blanco B; Herrero-Sánchez C; García JL; Carrancio S; Hernández-Campo P; González FJ; Flores T; Ciudad L; Ballestar E; Del Cañizo C; San Miguel JF; Pérez-Simon JA
Blood; 2010 Jan; 115(1):107-21. PubMed ID: 19887673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
